Search
forLearn
5 / 801 resultslearn phenoxyethanol
learn Piroctone Olamine
learn mometasone furoate
learn Aminomethyl Propanol
Research
5 / 1000+ resultsresearch Successful Topical Treatment of Murine Cutaneous Leishmaniasis with a Combination of Paromomycin (Aminosidine) and Gentamicin
The topical treatment WR 279,396 effectively healed cutaneous leishmaniasis in mice without relapse.
research Read-Through for Nonsense Mutations in Type XVII Collagen‒Deficient Junctional Epidermolysis Bullosa
A new therapy for a skin blistering condition has not been developed yet.
research Infant alopecia universalis: role of topical PUVA (psoralen ultraviolet A) radiation
Topical PUVA and tacrolimus ointment can effectively and safely treat infant alopecia universalis.
research Inhibitory effects of the ATP-sensitive potassium channel openers cromakalim, pinacidil and minoxidil on the carbachol–response curve in porcine detrusor muscle
Certain drugs can reduce bladder muscle contractions, potentially helping treat bladder diseases.
research Ketoconazole in cutaneous leishmaniasis
Ketoconazole cured about 70% of cutaneous leishmaniasis cases caused by Leishmania major.
Community Join
5 / 1000+ resultscommunity Pelage Pharmaceuticals with an absolute stunner of a molecule
PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.
community Mystery compound found to be safe and effective at treating hair loss. Details in comments.
A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.
community The story of RU58841/PSK3841
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
community Pelage PP405 Phase 2a completed.
Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss, with excitement around a new drug, PP405, and a reformulated oral minoxidil in trials. Concerns about cost, side effects, and long-term use are also mentioned.
community Polydopamine Synergizes with Quercetin Nanosystem to Reshape the Perifollicular Microenvironment for Accelerating Hair Regrowth in Androgenetic Alopecia.
A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.